MGCLF 0.01 MGC Pharmaceuticals Limited
| Range: | 0.225-5.1 | Vol Avg: | 192 | Last Div: | 0 | Changes: | 0.01 |
| Beta: | 0.97 | Cap: | 0.01B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Wed Feb 22 2017 | Empoloyees: | |||
| CUSIP: | CIK: | ISIN: | Country: | AU | |||
| CEO: | Mr. Roby Reuven Zomer | Website: | https://mgcpharma.com.au | ||||
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. The company also provides ArtemiC range of products and cannabinoid products, as well as non-pharma products. In addition, it offers consulting services, including clinical research services. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is based in West Perth, Australia.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow